FcγR requirements leading to successful immunotherapy
FcγR requirements leading to successful immunotherapy
Monoclonal antibody (mAb) immunotherapy is currently experiencing an unprecedented amount of success, delivering blockbuster sales for the pharmaceutical industry. Having experienced several false dawns and overcoming technical issues which limited progress, we are now entering a golden period where mAbs are becoming a mainstay of treatment regimes for diseases ranging from cancer to autoimmunity. In this review, we discuss how these mAbs are most likely working and focus in particular on the key receptors that they interact with to precipitate their therapeutic effects. Although their targets may vary, their engagement with Fcγ receptors (FcγRs) on numerous immune effector cells is almost universal, and here we review their roles in delivering successful immunotherapy.
104-122
Dahal, L.
1e993a7a-b007-4187-82ea-e28dd3920b66
Roghanian, A.
e2b032c2-60a0-4522-a3d8-56a768792f36
Beers, S.
a02548be-3ffd-41ab-9db8-d6e8c3b499a2
Cragg, M.
ec97f80e-f3c8-49b7-a960-20dff648b78c
November 2015
Dahal, L.
1e993a7a-b007-4187-82ea-e28dd3920b66
Roghanian, A.
e2b032c2-60a0-4522-a3d8-56a768792f36
Beers, S.
a02548be-3ffd-41ab-9db8-d6e8c3b499a2
Cragg, M.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Dahal, L., Roghanian, A., Beers, S. and Cragg, M.
(2015)
FcγR requirements leading to successful immunotherapy.
[in special issue: Fc Receptors]
Immunological Reviews, 268 (1), .
(doi:10.1111/imr.12342).
(PMID:26497516)
Abstract
Monoclonal antibody (mAb) immunotherapy is currently experiencing an unprecedented amount of success, delivering blockbuster sales for the pharmaceutical industry. Having experienced several false dawns and overcoming technical issues which limited progress, we are now entering a golden period where mAbs are becoming a mainstay of treatment regimes for diseases ranging from cancer to autoimmunity. In this review, we discuss how these mAbs are most likely working and focus in particular on the key receptors that they interact with to precipitate their therapeutic effects. Although their targets may vary, their engagement with Fcγ receptors (FcγRs) on numerous immune effector cells is almost universal, and here we review their roles in delivering successful immunotherapy.
This record has no associated files available for download.
More information
e-pub ahead of print date: 26 October 2015
Published date: November 2015
Organisations:
Faculty of Medicine
Identifiers
Local EPrints ID: 390361
URI: http://eprints.soton.ac.uk/id/eprint/390361
ISSN: 0105-2896
PURE UUID: 64dea7ac-0e25-41d8-88c6-1a43ce3bc90e
Catalogue record
Date deposited: 24 Mar 2016 14:43
Last modified: 15 Mar 2024 03:34
Export record
Altmetrics
Contributors
Author:
L. Dahal
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
